The pharmaceutical industry has evolved to better meet the needs of patients, with Medical Affairs playing a crucial role in drug development and commercialization. However, there are significant barriers to diversity in clinical trial participation, particularly among underrepresented racial and ethnic groups. Structural and personal barriers limit access to clinical trials, which can result in skewed data and limited treatment options for diverse populations. Medical Affairs can work to address these barriers by implementing patient-centric approaches, leveraging technology, and collaborating with stakeholders to build trust and increase trial participation among marginalized communities. This effort is crucial for advancing healthcare equity and improving treatment outcomes for all patients.
Source link
The Role of Medical Affairs in Bridging Clinical Trial Access for All Patients
